BMS-433771 dihydrochloride hydrate is a potent orally active inhibitor of respiratory syncytial virus (RSV). BMS-433771 dihydrochloride hydrate is active against both A and B groups of RSV, with an average EC₅₀ of 20 nM. BMS-433771 dihydrochloride hydrate can be used for the research of respiratory tract disease.

BMS-433771 dihydrochloride hydrate 对 A 组和 B 组 RSV 均具有抑制作用，平均 EC₅₀ 为 20 nM。
BMS-433771 dihydrochloride hydrate 可抑制病毒 F 蛋白诱导的膜融合。

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

BMS-433771 dihydrochloride hydrate (口服；1-200 mg/kg；每天 1 或 2 次，共 4 天) 通过口服给药显示出预防效果，但两种啮齿动物模型之间具有相当大的药效学差异
.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

BMS-433771 dihydrochloride hydrate (口服；1-200 mg/kg；每天 1 或 2 次，共 4 天) 通过口服给药显示出预防效果，但两种啮齿动物模型之间具有相当大的药效学差异
.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

• . Christopher Cianci, et al. Antiviral activity and molecular mechanism of an orally active respiratory syncytial virus fusion inhibitor. J Antimicrob Chemother  [Content Brief]

  . Christopher Cianci, et al. Oral efficacy of a respiratory syncytial virus inhibitor in rodent models of infection. Antimicrob Agents Chemother. 2004 Jul;48(7):2448-54.  [Content Brief]